Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia-论文-万方医学网

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

导出原文传递

翻译打印收藏纠错

作者： Fleischmann, Maximilian ^[1] ; Scholl, Sebastian ^[2] ; Frietsch, Jochen J. ^[3] ; Hilgendorf, Inken ; Schrenk, Karin ; Hammersen, Jakob ; Prims, Florian ; Thiede, Christian ; Hochhaus, Andreas ; Schnetzke, Ulf

作者单位： Friedrich Schiller University of Jena,Univ Klinikum Jena ^[1] Abt Hamatol & Onkol,SRH Klinikum Burgenlandkreis Naumburg ^[2] Med Klin 1,Univ Klinikum Carl Gustav Carus ^[3]

关键词 AML Venetoclax Hypo-methylating agents Refractory Relapse Salvage therapy MYELODYSPLASTIC SYNDROME HYPOMETHYLATING AGENTS DOSE CYTARABINE OLDER PATIENTS PHASE-III AZACITIDINE CHEMOTHERAPY REGIMENS OUTCOMES

发布时间 2022-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

相似文献

相关期刊

检索历史清除